Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer
Status:
Unknown status
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
Taxotere is the current standard first-line chemotherapy for mCRPC and may be used as
second-line therapy in good responders in first-line (Taxotere rechallenge). Jevtana has
demonstrated a survival benefit versus mitoxantrone in patients progressing during or after
Taxotere and is now the standard second-line chemotherapy. Taxotere and Jevtana have
different toxicity profiles.
Many patients who are receiving Jevtana for second-line treatment indicate they prefer this
agent over Taxotere with regards to the general tolerance (namely peripheral neuropathy, nail
changes, asthenia). This was not expected since Jevtana in post-Taxotere setting was
associated with more grade 3-4 adverse events such as febrile neutropenia and diarrhea than
Taxotere in first-line setting.
The study design of CABA-DOC is similar to that of the PISCES trial which evaluated the
patient preference between two standard treatments for first-line metastatic kidney cancer.
Despite similar PFS improvements over placebo in phase III trials, results clearly showed
that patients preferred pazopanib over sunitinib.
A randomized phase III study is currently comparing the efficacy of Taxotere and Jevtana in
first-line setting with overall survival as a primary end-point. Assessing patient preference
between Jevtana and Taxotere would contribute to further identify differences between these
two taxanes and clarify which one of these two taxanes should be used for second-line
chemotherapy and perhaps for first-line chemotherapy in the future.
Assessing patient preference between the two taxanes might be less biased in the first-line
setting where patients have no previous experience with a taxane.